

Galaxy Surfactants Ltd.

February 3, 2020

National Stock Exchange of India Ltd., Listing Compliance Department Exchange Plaza, C-1, Block G,

Bandra Kurla Complex,

Bandra (East)

Mumbai - 400 051

Scrip Symbol: GALAXYSURF

BSE Limited,

Listing Department,

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai- 400001

Scrip Code: 540935

Sub: Investor presentation & earnings release on Un-Audited Financial Results for the quarter ended December 31, 2019.

Ref: Regulation 30 (2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

We are enclosing Investor Presentation & earnings release on Un-audited Financial Results for the quarter ended December 31, 2019.

The information is also hosted in announcement section on the website of the Company at www.galaxysurfactants.com

We request you to take the same on record.

Yours faithfully,

For Galaxy Surfactants Limited

Niranjan Ketkar

Company Secretary

Encl: as above

Regd. Office:

C-49/2, TTC Industrial Area, Pawne, Navi Mumbai – 400 703, India. CIN No. U39877MH1986PLC039877

Ph: +91-22-65134444 / 27616666



















Safe Harbor



This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Galaxy Surfactants Limited.** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.





9M FY20 Performance Highlights

9MFY20: Key Developments



The AMET market outperformed on the back of a strong performance registered by the Performance Surfactants segment

Domestic (India) business registered healthy 4.8% (Y-O-Y) growth post two subdued quarters, showing signs of revival

All three regions report volume growth despite headwinds

Growth driven by all three customer segments: MNC's, Regional & Local


Emerging trends and diverse product portfolio ensured growth across product segments



Volume Highlights




Volume: 9MFY20 Highlights (YoY)



India Market grew by 0.7%




Specialty Care Products



Africa Middle East Turkey grew by 9.5%



Total Volume



Rest of the World grew by 6.8%




Both Performance & Specialty Care segments logged in growth which was ahead of the Industry growth rate



9MFY20 Highlights (YoY)







As per Ind AS

^Includes other Income

Consolidated Profit & Loss Statement



Particulars (Rs. In Crores)	Q3 FY20	Q3 FY19	Y-o-Y	9M FY20	9M FY19	Y-o-Y	FY19
Net Revenue from Operations	625.9	679.4	-7.9%	1,939.7	2,080.8	-6.8%	2,763.0
Other Income	3.4	1.0		5.9	1.2		4.7
Total Revenue	629.3	680.4	-7.5%	1,945.6	2,082.0	-6.5%	2,767.7
Cost of Material Consumed	421.6	477.1		1,297.5	1,481.9		1,948.1
Employee's Benefits Expense	43.2	39.7		131.6	117.7		164.6
Other Expenses	78.9	80.1		244.4	223.2		296.9
EBITDA	85.5	83.5	2.4%	272.2	259.3	5.0%	358.1
EBITDA Margin	13.6%	12.3%		14.0%	12.5%		12.9%
Depreciation	16.4	12.9		46.7	38.3		51.2
EBIT	69.1	70.6	-2.1%	225.5	221.0	2.0%	306.9
Finance cost	5.8	7.1		18.2	22.2		30.0
PBT	63.2	63.4	-0.3%	207.3	198.9	4.2%	276.9
Tax expense	15.2	21.6		39.7	65.0		85.9
PAT	48.0	41.8	14.7%	167.6	133.9	25.2%	191.0
PAT Margin	7.6%	6.2%		8.6%	6.4%		6.9%
Other Comprehensive Income	2.0	-12.4		10.7	21.5		18.3
Total Comprehensive Income	49.9	29.5		178.3	155.4		209.3
EPS	13.54	11.80		47.27	37.76		53.87

- Decline in revenue is primarily due to declining fatty alcohol prices. The same fell from an avg. rate of \$1,361/MT to \$1,138/MT YoY basis
- Average Forex rate in 9MFY20 was Rs. 70.36 per USD versus
 Rs 69.57 per USD in 9MFY19
- PAT includes deferred tax gain and savings on account of reduction in Corporate tax rate in India



Standalone Profit & Loss Statement



Particulars (Rs. In Crores)	Q3 FY20	Q3 FY19	Y-o-Y	9M FY20	9M FY19	Y-o-Y	FY19
Net Revenue from Operations	442.2	494.1	-10.5%	1,359.1	1,503.9	-9.6%	1,996.4
Other Income	-4.7	-0.8		4.0	32.1		35.9
Total Revenue	437.5	493.3	-11.3%	1,363.1	1,536.0	-11.3%	2,032.3
Cost of Material Consumed	300.6	352.2		917.5	1,091.2		1,432.7
Employee's Benefits Expense	21.8	20.9		70.2	63.6		87.3
Other Expenses	50.9	55.7		161.8	152.1		208.7
EBITDA	64.4	64.5	-0.2%	213.7	229.1	-6.8%	303.5
EBITDA Margin	14.7%	13.1%		15.7%	14.9%		14.9%
Depreciation	10.8	7.1		30.0	21.2		28.7
EBIT	53.6	57.4	-6.7%	183.7	207.9	-11.7%	274.8
Finance cost	4.3	4.7		13.3	14.7		20.4
РВТ	49.3	52.7	-6.6%	170.4	193.2	-11.8%	254.4
Tax expense	12.7	18.9		34.0	64.9		85.9
PAT	36.5	33.9	7.8%	136.4	128.3	6.3%	168.5
PAT Margin	8.3%	6.9%		10.0%	8.4%		8.3%
EPS	10.30	9.55		38.48	36.20		47.51

Other income for 9MFY20 includes loss of Rs 1.03 cr as against gain of Rs 29.22 cr in 9MFY19 in respect of financial assets (Preference Shares) mandatorily measured at fair value through profit & loss



Consolidated Balance Sheet



Particulars (Rs. In Crores)	Sept '19	Mar'19
ASSETS		
Property, Plant and Equipment	528.5	511.2
Right-of-use assets	38.9	0.0
Capital work-in-progress	111.8	82.6
Goodwill	2.6	2.5
Intangible Assets	5.6	5.0
Financial Assets		
(i) Investments	0.0	0.0
(ii) Loans	7.2	6.9
(iii) Other financial assets	0.9	1.9
Deferred Tax Assets (Net)	4.2	4.9
Income Tax Assets (Net)	17.0	8.0
Non-current tax assets	39.8	47.6
Total Non-Current Assets	756.5	670.6
Current Assets		
Inventories	352.0	351.3
Financial Assets		
(i) Trade receivables	417.4	426.8
(ii) Cash and cash equivalents	33.4	25.0
(iii) Bank Balances other than cash and cash equivalents	0.8	0.7
(iv) Loans	0.5	3.7
(v) Other Financial Assets	5.9	3.0
Other Current Assets	119.0	86.9
Total Current Assets	929.0	897.4
TOTAL ASSETS	1,685.5	1568.0

Particulars (Rs. In Crores)	Sept'19	Mar'19
EQUITY AND LIABILITIES		
EQUITY		
Equity Share Capital	35.5	35.5
Other Equity	956.8	841.3
Total Shareholders Fund	992.3	876.7
Non-Current Liabilities		
Financial Liabilities		
(i) Borrowings	63.4	89.2
(ii) Lease Liabilities	20.7	0.0
(iii) Other Financial Liabilities	0.3	0.3
Provisions	12.9	10.0
Deferred Tax Liabilities (Net)	24.6	32.0
Other non-current liabilities	0.4	0.8
Total Non-Current Liabilities	122.3	132.3
Current Liabilities		
Financial Liabilities		
(i) Borrowings	225.7	164.0
(ii) Trade Payables	258.2	305.9
(iii) Lease Liabilities	3.5	0.0
(iv) Other Financial Liabilities	62.0	71.5
Other Current Liabilities	13.8	8.5
Provisions	3.3	4.1
Current Tax Liabilities (Net)	4.4	5.1
Total Current Liabilities	570.9	559.0
TOTAL EQUITY & LIABILITIES	1,685.5	1568.0

Consolidated Cash Flow Statement



Doutioulous (Do. In Cuovas)	Half Year ended		
Particulars (Rs. In Crores)	Sept '19	Sept '18	
Cash Flow From Operating Activities :			
Profit After Tax	119.6	92.0	
Operating Profit before working Capital changes	183.7	172.9	
Net cash flows generated from/(used) in Operating Activities (A)	101.1	85.7	
Net cash flows generated from/(used) in Investing Activities (B)	-79.2	-75.6	
Net cash flows generated from/(used) in Financing Activities (C)	-14.1	-7.0	
Net Increase/(Decrease) in cash and cash equivalents (A+B+C)	7.8	3.1	
Opening cash and cash equivalents	25.0	27.1	
Effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies	0.6	3.0	
Closing cash and cash equivalents	33.4	33.2	



Standalone Balance Sheet



Particulars (Rs. In Crores)	Sept '19	Mar'19
ASSETS		
Property, Plant and Equipment	376.2	354.2
Capital work-in-progress	38.1	40.2
Right of use Asset	25.6	0.0
Intangible Assets	5.5	5.0
Financial Assets		
(i) Investments	261.8	256.5
(ii) Loans	5.4	5.3
(iii) Other financial assets	0.5	1.3
Deferred Tax Assets (Net)	0.0	0.0
Income Tax Assets (Net)	14.4	8.0
Non-current tax assets	36.3	45.5
Total Non-Current Assets	763.8	715.8
Current Assets		
Inventories	223.1	209.7
Financial Assets		
(i) Trade receivables	287.5	306.5
(ii) Cash and cash equivalents	4.4	3.9
(iii) Bank Balances other than cash and cash equivalents	0.8	0.7
(iv) Loans	0.4	3.5
(v) Other Financial Assets	7.0	3.8
Other Current Assets	83.4	62.9
Total Current Assets	606.5	590.9
TOTAL ASSETS	1,370.3	1,306.7

Particulars (Rs. In Crores)	Sept '19	Mar'19
EQUITY AND LIABILITIES		
EQUITY		
Equity Share Capital	35.5	35.5
Other Equity	833.1	747.1
Total Shareholders Fund	868.6	782.5
Non-Current Liabilities		
Financial Liabilities		
(i) Borrowings	63.4	89.2
(ii) Lease Liability	8.1	-
(iii) Other Financial Liabilities	0.3	0.3
Provisions	12.9	10.0
Deferred Tax Liabilities (Net)	35.1	41.3
Other non-current liabilities	0.4	0.5
Total Non Current Liabilities	120.2	141.2
Current Liabilities		
Financial Liabilities		
(i) Borrowings	84.4	28.5
(ii) Trade Payables	223.8	274.3
(iii) Lease Liability	2.1	0.0
(iv) Other Financial Liabilities	55.6	66.2
Other Current Liabilities	8.3	6.0
Provisions	2.9	3.7
Current Tax Liabilities (Net)	4.4	4.4
Total Current Liabilities	381.5	382.9
TOTAL EQUITY & LIABILITIES	1,370.3	1,306.7



Standalone Cash Flow Statement



Particulars (Ps. In Crores)	Half Year ended		
Particulars (Rs. In Crores)	Sept '19	Sept '18	
Cash Flow From Operating Activities :			
Profit After Tax	99.9	94.5	
Operating Profit before working Capital changes	142.5	130.1	
Net cash flows generated from/(used) in Operating Activities (A)	46.6	73.3	
Net cash flows generated from/(used) in Investing Activities (B)	-40.4	-50.6	
Net cash flows generated from/(used) in Financing Activities (C)	-5.8	-21.9	
Net Increase/(Decrease) in cash and cash equivalents (A+B+C)	0.4	0.7	
Opening cash and cash equivalents	3.9	1.9	
Effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies	0.0	0.0	
Closing cash and cash equivalents	4.3	2.7	



Business Overview



Truly Indian MNC...





Leading manufacturer of Ingredient for Home & Personal care Industry (HPC)



Product applications across Mass, Mass-tige & Prestige range of Customers



Preferred supplier to leading Multinational, Regional & Local FMCG Brands



Brand Custodian



Globally Recognized



Integrated Across Full Value Chain of HPC Industry



Advanced portfolio of Innovative Products & Solutions





... Vertically Integrated in HPC Industry





200+ Product Grades



7 Strategically Located
Facilities with Inhouse Project
Execution Capabilities
5 in India, 1 in Egypt, 1 in US



Extensive R&D Capabilities
74 Members, R&D Centre, Pilot
Plant, Product Application
Centre;



Indigenous Intellectual property 68 Approved; 18 Applied












We grow faster than HPC FMCGs



India's Largest Manufacturer of Oleochemical based Surfactants and Speciality Care Products for Home Care and Personal Care Industries (HPC)





Our growth trajectory over Three Decades

1992



1986: Incorporation of Company

1984: New Plant at Tarapur for

Ethoxylates, Phenoxyethanol, Sunscreens

1994: New plant set up at Tarapur

1995: Acquisition of Galaxy Chemicals

1997: Sulfonation plant Setup at Taloja and

Research Centre at Navi Mumbai

1998: Commissioning of new plant in Taloja

2004: setting up of EOU at Taloja

2009:

162

2004

- Acquisition of Tri-K Industries
- Galaxy Chemicals Egypt S.A.E. & Rainbow Holdings GmbH became step down subsidiary

382


2008

589

2010

2011: Commissioning of Egypt and Jhagadia Plants

2014: Purchase of business of Surfactants International LLC



1980 1984 1988 1990

1990-2000

1994

2000-2010

EXPORT GROWTH PHASE

322

2007

GLOBAL ESTABLISHMENT

2010 - 2019

IMPORT SUBSTITUTION

1980-1990

- Established credentials in surfactants/ specialty ingredients space
- Due to high import duties, personal care products were considered luxury goods Galaxy was a strong supplier for import substitution
- Developed a solid R&D base

INDIA GROWTH PHASE

1998

2000

- Post Economic Liberalisation, market for personal care products grew substantially
- Galaxy emerged as a strong player
- Grew exponentially led by strong innovation capabilities
- Focused on capturing the domestic market and large customer accounts
- Set up capacities to cater to the emerging requirements

■ Strategic shift with focus on Global

- markets expansion
- Made investments to acquire manufacturing facilities at USA, Egypt and established international offices
- Increased share of revenue from international business

- Dominant Share in India
- Increased Global Participations
- Supplier Recognitions (Global)
- Strong R&D Capability
- Customer Partnership
- IPO listing of the company on BSE and NSE

Accepted as Global Vendor benchmarked with best International peers



Our focus is Personal & Home Care Segment





... with over 200 Product Offerings



Performance Surfactants	Anionic Surfactants FAES, FAS, LABSA	✓ Foam and Dirt removal properties
Surfactants	Non-lonics Surfactants Ethoxylates	✓ Cosmetics and Personal care products as emulsifiers and solubilisers
	Amphoteric Surfactants Betaines	✓ Dermatological properties to reduces skin irritation
	Cationic Surfactants Quats	✓ Effective conditioning aids: substantively to hair and antimicrobial properties
	Sunscreen Agents (OMC, OCN &Others)	Absorb or block the harmful radiation, Mild for the skin with Moisturizing Reduced toxicity & prevent spoilage
Speciality Care Products	Preservatives, Preservative Blends Phenoxyethanol, Preservative Blends Surfactant Blends	Reduced toxicity & prevent spoilage
	Speciality Ingredients Mild Surfactants (MS), Proteins and Syndet & Transparent Bathing Bar Flakes	 MS: Cleanse adequately without compromising basic function of skin Protein: cosmetic industry for conditioning, protection and strengthening of hair/skin, anti-irritancy, moisturization etc
Bifurcation is only for Investor community as	Fatty Alkanolamides (FA) and Fatty Acid Easters (FAE)	✓ FA & FAE: Foam, viscosity boosters and pearlizer in a formulation
every product has different functionality	Other Care Products Conditioning Agents, Polyquats & Amine Oxides	✓ Improves the quality of another material also called as moisturizers, conditioning benefits to the hair etc



Our Business Segments...



Performance Surfactants

"Substantive Raw Material in Customer's End-products"

- Products are functional in nature where Endconsumer require foaming & cleansing
- Large volume consumption in all rinse-off formulations
- Products are Pulled by FMCG as it is required due to impulse buying from end consumer

Speciality Care Products

"Unique Functionality to Customer's End-products"

- Niche & Premium products
- Low volume consumption
- Oligopolistic for most products
- Low penetration due to its unique application

No. of Products

About Product







155 + products

Revenue Mix




62%

38%

Our Global Footprints










"Consumer to Chemistry": Creation of Products







...with World-class R&D facilities



Collaborative product development with Customers which helps Customers in choosing "Right Technology with Right Application"

Inhouse R&D Team of 74 professionals comprising of doctorates, chemists and engineers

Well-Equipped R&D Centre, Pilot Plant at Tarapur, Maharashtra; Product applications centre for proteins at Denville, USA

Innovation Funnel (adopted in 2007) to consistently diversify product offerings, meet customer needs and consumer trends











State-of-the-art Manufacturing Facilities




Location	No. of Units	Installed Capacity	Details
Tarapur, Maharashtra	3	33,647 MTPA	 ✓ 1 pilot plant for scale up and commercialisation of new products rolling out from R&D activities ✓ Easy access to the Jawaharlal Nehru Port Trust, Navi Mumbai
Taloja, Maharashtra	1	153,741 MTPA	 ✓ One of the largest sulfation facilities in India ✓ Easy access to the Jawaharlal Nehru Port Trust, Navi Mumbai
Jhagadia, Gujarat*	1	131,000 MTPA	✓ Located close to raw material source ethylene oxide
Suez, Egypt*	1	117,500 MTPA	 ✓ Located in the Attaqa Public Free Zone, exempt from all direct and indirect taxes ✓ Access to the Suez Canal, can address AMET, Europe and Americas (North and South) markets
New Hampshire, USA	1	600 MTPA	✓ Step-down Subsidiary - Tri-K Industries owns and operates for different grades of proteins for cosmetic applications

*Environmental clearances for expansion and additional land available at Jhagadia and Suez plants



1750+ Clients across 75+ Countries





Long term strategic relationship with all of the top 10 customers

Strict qualifications and extensive collaboration with customers for end-product development

FY19: Revenue Contribution

MNC Customers: 56% Regional Players: 10% Local & Niche Player: 34% Through Innovation funnel, Demonstrated Engineering & Technical excellence All FMCG Protocols accomplished by us which helped to create Decade old partners Of basket of 200+ products, clients has various requirement with different quantity with different pricing mechanism

Galaxy has created Integrated Value chain for long lasting relationship



Awards & Certifications: True recognition of Capabilities



Recognition from Clients



"Certificate of Excellence in Samyut", 2017



"Best Supply Partner", 2015
"Winning through
Innovation" at the Partner
to Win, 2012 Awards

"Innovation Award" for Green Catalyst and Sustainability at the Partner to Win, 2014 Awards L'ORÉAL "

COLGATE-PALMOLIVE

Award of Global Performance" for L'Oréal Asia Pacific 2012 "Certificate of Appreciation", 2008

"Certificate of Recognition",

2014



2018

Long Standing Partner Award Best Reliable Partner Award Best Value Addition Award



Certificate of Appreciation For valuable association as a Business Partner

Innovation Zone



Received Gold Medal for "Galsoft GLI21", Organized by HPCI, ISCC and SOFW



Iconic Company
Indian HPC Industry
Association



"Gold Award", Castor Oil and Specialty Chemicals Panel for export performance in large scale sector for the years 2011-2012, 2012-2013 and 2015-2016. Trishul Award in 2017 for the outstanding export performance







EcoVadis *Galaxy Group*



Responsible Care, India



"Great Place to Work" for the Fiscal 2017-2018



"Silver Medal" in India Green Manufacturing Challenge 2016 for Jhagadia unit



"Certificate of Appreciation" in occupational safety & health by National Safety Council of India for Taloja Plant, 2011



"Special Award for TPM Achievement", 2008



"Certificate of Merit 2008 – Manufacturing Category" in the IMC Ramkrishna Bajaj National Quality Award 2008"



Certifications

Accolades Received during FY19



Recognition from Clients

Unilever

""Outstanding Contribution to PARTNER TO WIN" by Unilever during ACI-2019 conference



"Emerging Business Partner - 2018" awarded by Abbott at Samanvay 2018 event

ICIS Innovation Award 2018

Best Process Innovation

for our "Green Process for the manufacture of Amino Acid Surfactants"

Innovation Award

Best Ingredient Award- SILVER

at HPCI 2019, Mumbai, for our product 'Galguard NT'

CHEMEXCIL

Trishul Award -

for the year 2016, awarded in Apr 2018



for GCE and Jhagadia

OHSAS 18001:2007

for GCE and Jhagadia

RSPO MB and SG models for GSL

ISO 9001:2015

for GSL all sites and for GCE

Cosmetic GMP

(ISO 22716:2007) for Jhagadia

4-pillar SMETA for Tarapur (M3 and G59), Taloja and GCE







Management Team on Board





Mr. Unnathan Shekhar Promoter, Managing Director

- Associated with Company since 1986
- •Chemical Engineer, PGDM from IIM, Calcutta



Mr. Natarajan K. Krishnan
Executive Director, Chief Operating Officer

- Associated with Company since 1993
- •CWA, Advanced Management Program from Harvard Business School



Mr. Kasargod Ganesh Kamath
Executive Director (Finance), Chief Financial
Officer

- Associated with Company since 2004
- Qualified CS, CWA and LL.B, over 20 years of experience



Dr. Nirmal Koshti Non-Executive Director

- Associated with Company since 1986
- Ph. D. in Organic Chemistry (University of Bombay); Extensive post-doctoral research experience



Mr. Vaijanath Kulkarni Non-Executive Director

- Associated with Company since 1995
- •Chemical Engineer
- •Currently, MD of Galaxy Chemicals (Egypt) S.A.E



Along with Guidance of Senior Board Members





Mr. Shekhar Ravindranath Warriar Chairman, Non-Executive Independent Director

- Associated with Company since 2007
- •More than 30 years with Unilever, India in various capacities



Mr. Gopalkrishnan Ramakrishnan Promoter, Non-Executive Director

- Associated with Company since 1986
- Qualified CA and CS



Mr. Shashikant R. Shanbhag Promoter, Non-Executive Director

- •Associated with Company since 1986
- Qualified CA



Mr. Subodh S. Nadkarni Non-Executive Independent Director

- Associated with Company since
 2002, 30 years+ experience
- •Qualified CA and CS, prior associations with Godrej and Sulzer



Mr. Uday Kamat Non-Executive Additional Director

- •Associated with Company for 15+ years
- •Qualified CA and Cost Accountant, (ICWA)



Mr. Melarkode G. Parameswaran Non-Executive Independent Director

- Associated with Company since 2005
- •Chemical Engineer from IIT Madras; PGDM from IIM Calcutta; PhD from Mumbai University



Ms. Nandita Gurjar Non-Executive Independent Director

- Associated with Company since 2015
- •Over 20 years of experience in the field of IT and Human Resource



The 4 Cs: Our Core Strength





CHARACTER

Transparent & Open, Respect & Value People, Dreaming & Envisioning, Conducting Business with Integrity





COMPETENCE

Talented Team which proactively meets Complex & Changing Business Needs



COMPETITIVENESS

Adhering to Global Quality Standards, Supplying Customers Globally, Agile & Nimble Footedness



COMFORT

Respecting our Commitments, Consistent Performance over the years of Timely Delivery & Quality Consistency




High Growth Industry



Personal & Home Care: Stable & Non-Cyclical Industry






Galaxy has a strong presence in High Growth Markets of India and AMET Regions



Within Surfactants – Personal Care is fastest Growing Segment








All figures in USD billion Source: Company IPO Prospectus 33

Within Specialty – Personal Care Ingredients has largest Growth Potential







UV Absorbers Sunscreen

 Global sun care (of which 80% is sun protection) is a USD 11 bn market and is estimated to touch USD 12.3 bn by 2021

Preservatives & Preservative Blends

 Preservatives blends are special customized formulations of preservatives. The preservative blends market was values at USD 133.5mn in 2017 and is expected to grow at a CAGR of 6% to USD 210 mn by 2024

~15-20% Market Share
in
Global HPC Phenoxyethanol
Market

Mild Surfactants

 Surfactants milder than Traditional Agents are known as Mild Surfactants. These have been shown to cleanse adequately without compromising the skins basic function






Growth Strategy

Personal & Home Care: High Entry Barrier Businesses







Our Growth Vision



Sales Optimization



Increased focus on
high margin
products in both
the categories

R&D and Innovation



Continue to focus
on R&D and
Product Innovation
as a part of
"Consumer to
Chemistry
Approach"

Customer Wallet share



Increase Wallet
Share with Existing
Customers and
Continued Focus to
Expand Customer
Base

Market Strategy



Mutually
Complimentary
Two-pronged
Strategy to drive
growth in both
Emerging and
Matured Market

Profitability



Improve Financial
Performance
through Sales
Optimization,
Operational
Efficiencies &
Functional
Excellence







Managing Volatility in Raw Material Prices and Currency...



Fatty Alcohol Prices (USD / MT)

INR / USD Prices





... through Robust Risk Management Practices




Source: Market Prices – ICIS – LOR Source: RBI 39

Volume Highlights


Volume: FY19 Highlights (YoY)




Performance Surfactants



Specialty Care Products



Total Volume



India Growth 12%



Africa Middle East Turkey de-grew by -5%



Rest of the World grew by 29%




AMET Markets decline recouped by high growth in Specialty care products



FY19 Highlights (YoY)







As per Ind AS ^In

Our Performance Highlights





191


FY19*

158

FY18*













Our Balance Sheet Strength













*As per Ind AS rest as per Indian GAAP

Consolidated Balance Sheet



Particulars (Rs. In Crores)	Mar'19	Mar'18
ASSETS		
Property, Plant and Equipment	511.2	439.9
Capital work-in-progress	82.6	24.9
Goodwill	2.5	2.4
Intangible Assets	5.0	4.5
Financial Assets		
(i) Investments	0.0	0.1
(ii) Loans	6.9	5.7
(ii) Other financial assets	1.9	1.1
Deferred Tax Assets (Net)	4.9	3.4
Income Tax Assets (Net)	8.0	10.5
Non-current tax assets	47.6	44.0
Total Non-Current Assets	670.6	536.5
Current Assets		
Inventories	351.3	345.6
Financial Assets	:	
(i) Trade receivables	426.8	418.2
(ii) Cash and cash equivalents	25.0	27.1
(iii) Bank Balances other than cash and cash equivalents	0.7	0.5
(iv) Loans	3.7	4.3
(v) Other Financial Assets	3.0	5.0
Other Current Assets	86.9	118.1
Total Current Assets	897.4	918.9
TOTAL ASSETS	1,568.0	1,455.4

Particulars (Rs. In Crores)	Mar'19	Mar'18
EQUITY AND LIABILITIES		
EQUITY		
Equity Share Capital	35.5	35.5
Other Equity	841.3	683.3
Total Shareholders Fund	876.7	718.8
Non-Current Liabilities		
Financial Liabilities		
(i) Borrowings	89.2	72.2
(ii) Other Financial Liabilities	0.3	0.3
Provisions	10.0	6.1
Deferred Tax Liabilities (Net)	32.0	27.7
Other non-current liabilities	0.8	0.9
Total Non Current Liabilities	132.3	107.2
Current Liabilities		
Financial Liabilities		
(i) Borrowings	164.0	219.7
(ii) Trade Payables	305.9	327.8
(iii) Other Financial Liabilities	71.5	60.0
Other Current Liabilities	8.5	17.8
Provisions	4.1	4.1
Current Tax Liabilities (Net)	5.1	0.1
Total Current Liabilities	559.0	629.4
TOTAL EQUITY & LIABILITIES	1,568.0	1,455.4



As per Ind AS 44

Standalone Balance Sheet



Particulars (Rs. In Crores)	Mar'19	Mar'18
ASSETS		
Property, Plant and Equipment	354.2	277.9
Capital work-in-progress	40.2	18.5
Goodwill	0	0
Intangible Assets	5.0	3.2
Financial Assets		
(i) Investments	256.5	223.1
(ii) Loans	5.3	4.1
(ii) Other financial assets	1.3	0.7
Deferred Tax Assets (Net)	0.0	0.0
Income Tax Assets (Net)	8.0	7.2
Non-current tax assets	45.5	43.8
Total Non-Current Assets	715.8	578.5
Current Assets		
Inventories	209.7	222.5
Financial Assets		
(i) Trade receivables	306.5	330.1
(ii) Cash and cash equivalents	3.9	1.9
(iii) Bank Balances other than cash and cash equivalents	0.7	0.5
(iv) Loans	3.5	3.4
(v) Other Financial Assets	3.8	5.5
Other Current Assets	62.9	95.4
Total Current Assets	590.9	659.4
TOTAL ASSETS	1,306.7	1,237.9

Particulars (Rs. In Crores)	Mar'19	Mar'18
EQUITY AND LIABILITIES		
EQUITY		
Equity Share Capital	35.5	35.5
Other Equity	747.1	630.4
Total Shareholders Fund	782.5	665.9
Non-Current Liabilities		
Financial Liabilities		
(i) Borrowings	89.2	67.9
(ii) Other Financial Liabilities	0.3	0.3
Provisions	10.0	6.1
Deferred Tax Liabilities (Net)	41.3	29.2
Other non-current liabilities	0.5	0.5
Total Non Current Liabilities	141.2	103.9
Current Liabilities		
Financial Liabilities		
(i) Borrowings	28.5	102.7
(ii) Trade Payables	274.3	299.4
(iii) Other Financial Liabilities	66.2	50.9
Other Current Liabilities	6.0	11.0
Provisions	3.7	4.0
Current Tax Liabilities (Net)	4.4	0.0
Total Current Liabilities	382.9	468.1
TOTAL EQUITY & LIABILITIES	1,306.7	1,237.9



As per Ind AS 45









CIN No: L39877MH1986PLC039877

Mr. Paritosh Srivastava

Email: Paritosh.Srivastava@galaxysurfactants.com

www.galaxysurfactants.com

Investor Relations Advisors:

SGA Strategic Growth Advisors

CIN - U74140MH2010PTC204285

Mr. Varun Divadkar/ Ms Neha Shroff

Varun.divadkar@sgapl.net / neha.shroff@sgapl.net

+91 9763702204/ +91 7738073466

www.sgapl.net







Galaxy Surfactants Limited

9MFY20 Consolidated Performance:

- Total volume grew by 5.6% for 9MFY20, on YoY basis
- Total Revenue (including other income) stood at Rs. 1,945.6 Cr, a YoY degrowth of 6.5% on account of lower fatty alcohol prices which declined by 6.7% for the guarter and 16.4% for 9MFY20.
- EBITDA stood at Rs. 272.2 Cr, YoY growth of 5.0%
- PAT stood at Rs. 167.6 Cr, YoY growth of 25.2% on the back of deferred tax gain and savings on account of reduction in corporate tax rate

Mumbai, 3rd February 2020:

Galaxy Surfactants Limited, a leading manufacturer of performance surfactants and specialty care products with over 200 product grades used in Home and Personal Care industry, has announced its unaudited financial results for the Quarter and Nine months ended December 31st, 2019.

-6.5%


PAT

1,946

9MFY20

168

9MFY20







Investors Release

Commenting on the performance Mr. U. Shekhar, Managing Director, Galaxy Surfactants Limited said

"Q-3 marked a mixed quarter for us. While on one hand we had the Indian market making a comeback registering a healthy 4.8% volume growth, the ROW Market due to the seasonal holidays in the developed markets saw a decline of 15.1%. This we believe is a one off and we do see the momentum coming back in the ensuing quarters. Egypt after registering a healthy growth of 29.8% in Q-2 FY 20, saw yet another quarter of good performance. AMET registered a healthy 14.2% growth for Q-3 FY 20, primarily driven by the 34.1% growth logged in by the Egypt Market.

The Performance Surfactants segment registered a healthy volume growth of 10.2% YoY driven by the AMET market. Specialty Care Products segment was impacted by the seasonality in the ROW markets during the quarter. We expect this segment to revert to growth in the coming quarter on the back of the strong acceptance and reach of our Specialty Care products portfolio.

Revenue saw a decline primarily due to the declining Fatty Alcohol prices, which is the major raw material for our performance surfactants. The same fell from an average rate of 1,273 USD/MT (Q3FY19) to 1,188 USD/MT in the current quarter (decline of 6.7%).

Overall while this quarter has been subdued, the fact that we have registered volume growth across all regions despite the headwinds makes us optimistic. The inherent strength of our business model has ensured we grow on all counts – Volumes across all regions and segments, EBITDA and PBT, despite higher depreciation and incremental costs on account of operationalization of our new plant.

Given the emerging global headwinds due to the Coronavirus which can have major repercussions not only on the global economy but also impact global consumption, we remain cautiously optimistic"

Performance Highlights:

Galaxy Surfactants Limited (Consolidated Results)			
Particulars (Rs. Cr)	9MFY20	9MFY19	YoY%
Total Revenue*	1,945.6	2,082.0	-6.5%
EBITDA*	272.2	259.3	5.0%
PAT	167.6	133.9	25.2%

^{*}Includes other income







Galaxy Surfactants Limited (Volume Break up): 9MFY20		
Particulars	YoY Growth % (9MFY20 vs 9MFY19)	
Sales Volume	5.6%	
ROW	6.8%	
India	0.7%	
AMET	9.5%	

- Total volumes stood at 1,66,107 MT for 9MFY20 as against 1,57,261 MT in 9MFY19, up by 5.6% YoY
 - o Volume growth has been driven by all three MNC, Regional and Local players
 - o ROW markets grew at 6.8% driven by Specialty Care Products
 - O Subdued demand led to a 0.7% growth in the India Market
 - o AMET market grew by 9.5% due to recovery in the Egypt market
 - o Performance Surfactants volume stood at 1,04,668 MT for 9MFY20, up by 7.1% on YoY basis
 - o Specialty Care Products volume stood at 61,439 MT for 9MFY20, up by 3.1% on YoY basis
- EBITDA for 9MFY20 stood at Rs. 272.2 Cr as against Rs. 259.3 Cr in 9MFY19, up by 5.0% YoY
- EBITDA/MT remained stable at Rs. 16,387 for 9MFY20 as against Rs. 16,489 in 9MFY19
- PAT stood at Rs. 167.6 Cr for 9MFY20 as against Rs. 133.9 Cr in 9MFY19 up by 25.2% YoY





Investors Release

About Galaxy Surfactants Limited:

Incorporated in 1986, Galaxy Surfactants Ltd is leading manufacturers of Performance Surfactants and Specialty Care products with over 200 product grades. These products are used in consumer-centric Home and Personal care products like hair care, oral care, skin care, cosmetics, soap, shampoo, lotion, detergent, cleaning products etc.

Preferred suppliers to leading MNC's, Regional and Local FMCG brands. Our key customers include Unilever, Reckitt Benckiser, P&G, L'OREAL, Himalaya, Colgate Palmolive, CavinKare etc.

Company has its manufacturing facilities located in India (5), Egypt (1) and USA (1).

For more information about the company, please visit our website www.galaxysurfactants.com

Safe Harbor:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Company	Investor Relations Advisors
Galaxy Surfactants Limited	Strategic Growth Advisors Pvt Ltd.
CIN No: L39877MH1986PLC039877	CIN No: U74140MH2010PTC204285
Name: Mr. Paritosh Srivastava	Mr. Varun Divadkar / Ms. Neha Shroff
Email id: paritosh.srivastava@galaxysurfactants.com	Email id: <u>Varun.divadkar@sgapl.net</u> / <u>neha.shroff@sgapl.net</u>
	Tel No: +91 9763702204 / +91 7738073466